Result of Spanish CardioQ-ODM

RNS Number : 5783H

Deltex Medical Group PLC

06 November 2008

 



Deltex Medical Group plc

CardioQ-ODM reduces lengths of stay in Spain by six days

6 November 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the UK's leading haemodynamic monitoring company and global leader in oesophageal Doppler monitoring ('ODM'), announces today the results of a multi-centre audit of the CardioQ-ODM™ in Spain.

Over 3,000 surgeons at the Congreso Nacional de Cirugia in Madrid heard the first findings of the eleven hospitals to have collated data on the impact of introducing CardioQ-ODM as part of an enhanced recovery programme in colorectal surgery.

Dr Ramirez, the lead colorectal surgeon from Hospital General Universitario Zaragoza, reported that the average (mean) length of stay had been reduced by six days per patient. After the introduction of CardioQ-ODM as part on an enhanced recovery protocol, patients were discharged after six days, whereas previously they had stayed in hospital for twelve days.

The results of the audit are being studied by representatives of the Entralgo Agency, which makes recommendations to the Spanish healthcare system about the clinical and cost effectiveness of medical innovations. A draft health technology assessment by this Agency, based on results from UK randomised controlled trials, indicated that using the CardioQ-ODM would save €900 per patient, reduce mortality rates and significantly reduce complications: the draft conclusions, although contingent on outcomes from the above audit, were already assessed as 'robust'.

Deltex Medical's Chief Executive, Andy Hill commented:

'These results confirm that we have created a major opportunity to establish a very large, high quality business in Spain. The country's leading surgeons are recommending new packages of care with ODM as the key single innovation and they are already looking beyond colorectal surgery to other types of major surgery. The Spanish government agencies that determine funding priorities have been involved throughout the audit and should now be able to finalise their positive draft health technology assessment and recommend ODM as a standard of care.'

For further information, please contact:-

Deltex Medical Group plc                          01243 774 837

Nigel Keen, Chairman                                  [e-mail]

Andy Hill, Chief Executive                            [e-mail]

Ewan Phillips, Finance Director                    [e-mail] 

Gavin Anderson & Company                     0207 554 1400

Deborah Walter                                          [e-mail]

Robert Speed                                             [e-mail]

Nominated Adviser & Broker

Charles Stanley Securities                       020 7149 6000

Philip Davies                                              [e-mail] 

Russell Cook                                             [e-mail] 

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

MSCFSSSAMSASELF